Nevirapine (NVP) Resistance in Women with HIV‐1 Subtype C, Compared with Subtypes A and D, after the Administration of Single‐Dose NVP

Abstract

ObjectiveIn the Human Immunodeficiency Virus (HIV) Network for Prevention Trials (HIVNET) 012 trial in Uganda, 6–8 weeks after single-dose nevirapine (SD-NVP), NVP resistance mutations were detected at a higher rate in women with HIV-1 subtype D than in women with subtype A. Here, we evaluate the rate of NVP resistance mutations in women with subtype C